Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU [fluorouracil] combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma.

X
Trial Profile

A phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU [fluorouracil] combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Cisplatin; Fluorouracil; Folinic acid
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms CapRI
  • Most Recent Events

    • 24 Sep 2012 Results published in the Journal of Clinical Oncology.
    • 07 Jun 2010 Primary endpoint 'Overall-survival-duration' has not been met.
    • 07 Jun 2010 Results were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top